Innocan Pharma Corporation

Recent News

  • Innocan Pharma Announces the Filing of a PCT Patent Application for its CBD Delivery System Technology in 153 Countries

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 4, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that a new patent application has been filed for Innocan's CBD Delivery System Technology, alongside the existing LTP (CBD Loaded Liposomes) and CLX (CBD Loaded Exosomes). The new patent application discloses a unique and novel delivery system allowing the controlled release of CBD into the blood stream with improved pharmacokinetic (PK) performance....

    2021-10-04 4:12 PM EDT
  • Innocan Pharma Announces the Filing by Ramot at Tel Aviv University of an International Patent Application for its Unique Cannabinoids Loaded Exosome Delivery Platform (CLX)

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 24, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), hereby announces the filing by Ramot of a new patent application for a unique Cannabinoids exosome delivery platform - CLX, developed by Ramot and their researchers from Tel Aviv University. InnoCan holds worldwide exclusive option agreement to develop and commercialese the CLX and noticed Ramot on the intention to execute the option into full license agreement....

    2021-09-24 4:00 PM EDT
  • Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it has conducted a recent experimental study of its CBD-loaded liposome technology (LPT) on large animals that demonstrated a similar pharmacokinetic profile as was demonstrated in a previous small animal study. This result is expected to bring the Company closer to clinical trials in humans.Pharmacokinetics (PK) determines the profile of drug...

    2021-09-03 4:00 PM EDT
  • Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 27, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") reports today, that since January 1st, 2021, it has received proceeds of approximately CAD $8.2M as a result of the exercise of approximately 32.9 Million previously issued common share purchase warrants and broker warrants. As a result, over 94% of Innocan's Warrants dated back to June 2020 and over 95% of its September 2019 warrants have...

    2021-08-27 4:00 PM EDT
  • Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 18, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that, following the early indications of its CBD Loaded Exosomes platform (CLX), the Company has issued a notice to Ramot, the Technology Transfer Company of Tel Aviv University (TAU), declaring the Company's intention to exercise its option to enter into a full Research and License Agreement with Ramot (the "Agreement").

    2021-08-18 3:00 AM EDT
  • Innocan Engages Ayurcann Inc. to Manufacture and Distribute Innocan's CBD Topicals in Canada

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce its been engaged into a manufacturing and distribution agreement dated August, 2021 (the "Manufacturing and Distribution Agreement") with Ayurcann Inc. ("Ayurcann"), a major Health Canada licensed producer and distributor of CBD products. Pursuant to the terms of the Manufacturing and Distribution Agreement, Innocan has engaged Ayurcann to manufacture Innocan's CBD Topicals...

    2021-08-11 3:00 AM EDT
  • Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 3, 2021) -  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to issue an update on its cutting-edge pre-clinical studies and on the development progress of its Liposome/CBD delivery platform (LPT). These studies are led by Dr. Ahuva Cern and Prof. Chezy Barenholz of The Hebrew University of Jerusalem. To date, Innocan completed two pre-clinical trials on animals. The first trial demonstrated no side effects,...

    2021-08-03 2:53 AM EDT
  • Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 28, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") filed a patent application for its topical composition for hair loss treatment. The patent application discloses and claims several compositions for topical administration comprising cannabinoid for the treatment and prevention of hair loss. Hair loss is the one of the most common syndromes faced by most of the people around the globe. The global hair...

    2021-07-28 4:00 PM EDT